Feed Top Reports Pricing

⌘K

00:15:11·1849d

SECFiling

SEC Form EFFECT filed by Urovant Sciences Ltd.

UROV· Urovant Sciences Ltd.

Health Care

Original source

Companies

UROV
Urovant Sciences Ltd.
Health Care

Related

PR1508d
Urovant Sciences Announces Positive Topline Results of Phase 2a Trial of its Potential Novel Gene Therapy, URO-902
PR1585d
Urovant Sciences Announces Publication in Advances in Therapy of Analyses of Patient-Perceived Meaningfulness of Improvement in Symptom Reduction for Overactive Bladder Patients Treated with GEMTESA® (vibegron) 75 mg
PR1627d
Urovant Sciences Announces Publication in Blood Pressure Monitoring of Positive Ambulatory Blood Pressure Study Results for GEMTESA® (vibegron) 75 mg in Overactive Bladder Patients
SEC1841d
SEC Form 15-12B filed by Urovant Sciences Ltd.
INSIDER1849d
SEC Form 4: E. Bryan Smith disposed to the issuer $0 worth of Common Shares (124,447 units at $0.00), decreasing direct ownership by 100% to 0 units
INSIDER1849d
SEC Form 4: Sef Kurstjens disposed to the issuer $0 worth of Common Shares (21,480 units at $0.00), decreasing direct ownership by 100% to 0 units
INSIDER1849d
SEC Form 4: M. James Hindman disposed to the issuer $0 worth of Common Shares (9,000 units at $0.00), decreasing direct ownership by 100% to 0 units
INSIDER1849d
SEC Form 4: Cornelia Haag-Molkenteller disposed to the issuer $0 worth of Common Shares (141,348 units at $0.00), decreasing direct ownership by 100% to 0 units

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releases Analyst ratings Insider trading FDA SEC RSS feeds

Top lists

Trending By market cap Active companies Analyst upgrades Insider purchases FDA approvals SEC filings Sectors Market reports

Company

About Pricing Publish with us Contact

Legal

Terms of use Privacy policy Cookie policy

© 2026 quantisnow.com · Democratizing insights since 2022